Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Sees Significant Growth in Short Interest

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw a large increase in short interest in July. As of July 15th, there was short interest totaling 63,921 shares, an increase of 109.1% from the June 30th total of 30,569 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average trading volume of 505,096 shares, the days-to-cover ratio is presently 0.1 days.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on CHGCY. Zacks Research raised shares of Chugai Pharmaceutical to a “hold” rating in a research report on Friday, May 29th. The Goldman Sachs Group upgraded shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a report on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Buy”.

Chugai Pharmaceutical Stock Performance

CHGCY opened at $21.42 on Thursday. Chugai Pharmaceutical has a one year low of $19.50 and a one year high of $34.84. The company has a market cap of $70.50 billion, a P/E ratio of 23.28 and a beta of 0.59. The business’s 50-day simple moving average is $23.17 and its 200-day simple moving average is $26.28.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its quarterly earnings results on Friday, July 24th. The company reported $0.22 EPS for the quarter. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.71%. The firm had revenue of $2.14 billion for the quarter, compared to analyst estimates of $2.38 billion. As a group, analysts predict that Chugai Pharmaceutical will post 0.98 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.